

William J. Brady

Amit Anil Kumar Pandit

Mark R. Sochor

## REFERENCES

1. Ayangco L, Rogers RS III: Oral manifestations of erythema multiforme. *Dermatol Clin* 21: 198, 2003. [PMID: 1262281]
2. French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. *Allergol Int* 55: 9, 2006. [PMID: 17075281]
3. Mockenhaupt M: Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. *Semin Cutan Med Surg* 33: 10, 2014. [PMID: 25037254]
4. Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al: Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. *Br J Dermatol* 168: 726, 2013. [PMID: 23413807]
5. Moreau JF, Watson RS, Hartman ME, Linde-Zwirble WT, Ferris LK: Epidemiology of ophthalmologic disease associated with erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis in hospitalized children in the United States. *Pediatr Dermatol* 31: 163, 2014. [PMID: 23679157]
6. Levin J, Hofstra T: Recurrent erythema multiforme. *JAMA* 312: 426, 2014. [PMID: 25038360]
7. Kakourou T, Klontza D, Soteropoulou F, Kattamis C: Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. *Eur J Pediatr* 156: 90, 1997. [PMID: 9039508]
8. Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP: Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. *Am J Med* 129: 1221, 2016. [PMID: 27086495]
9. Kelemen JJ, Cioffi WG, McManus WF, et al: Burn center care for patients with toxic epidermal necrolysis. *J Am Coll Surg* 180: 273, 1995. [PMID: 7874336]
10. Roujeau JC, Kelly JP, Naldi L, et al: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. *N Engl J Med* 333: 1600, 1995. [PMID: 7477195]
11. Tseng J, Maurer T, Mutizwa MM: HIV-associated toxic epidermal necrolysis at San Francisco General Hospital. *J Int Assoc Provid AIDS Care* 16: 37, 2017. [PMID: 26685211]
12. Khambaty MM, Hsu SS: Dermatology of the patient with HIV. *Emerg Med Clin N Am* 28: 355, 2010. [PMID: 20413018]
13. Paulmann M, Mockenhaupt M: Severe drug hypersensitivity reactions: clinical pattern, diagnosis, etiology and therapeutic options. *Curr Pharm Design* 22: 6852, 2016. [PMID: 27779083]
14. Wei CY, Ko TM, Shen CY, Chen YT: A recent update of pharmacogenomics in drug-induced severe skin reactions. *Drug Metab Pharmacokinet* 27: 132, 2012. [PMID: 22041139]
15. Sullivan JR, Shear NH: The drug hypersensitivity syndrome: what is the pathogenesis? *Arch Dermatol* 137: 357, 2001. [PMID: 11255340]
16. Cacoub P, Musette P, Descamps V, et al: The DRESS syndrome: a literature review. *Am J Med* 124: 588, 2011. [PMID: 21592453]
17. Wolkenstein P, Revuz J: Drug-induced severe skin reactions—incidence, management and prevention. *Drug Saf* 13: 56, 1995. [PMID: 8527020]
18. Tas S, Simonart T: Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome). *Dermatology* 206: 353, 2003. [PMID: 12771485]
19. Dominguez A, Cardeñosa N, Izquierdo C, et al: Prevalence of *Neisseria meningitidis* carriers in the school population of Catalonia, Spain. *Epidemiol Infect* 127: 425, 2001. [PMID: 11811875]
20. Caugant DA, Høiby EA, Magnus P, et al: Asymptomatic carriage of *Neisseria meningitidis* in a randomly sampled population. *J Clin Microbiol* 32: 323, 1994. [PMID: 8150942]
21. Anderson J, Berthelsen L, Bech Jensen B, Lind I: Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits. *Epidemiol Infect* 121: 85, 1998. [PMID: 9747759]